Spoken Alpha
ABBOTT LABORATORIES
Abbott Laboratories manufactures and sells a diversified portfolio of healthcare products across four segments: branded generic pharmaceuticals marketed primarily in emerging markets outside the U.S.; diagnostic systems and tests for blood banks, hospitals, and laboratories; pediatric and adult nutritional products sold to consumers and institutions; and cardiovascular, diabetes care, and neuromodulation medical devices sold globally to hospitals, physicians, and consumers.
ABBOTT LABORATORIES is a Healthcare company operating in Medical Devices with a $178.38B market cap.
Most recent reported earnings: Q3 FY2026 (Oct 20, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ABT.
$ curl https://api.spokenalpha.com/v1/companies/ABTFAQ
Spoken Alpha indexes ABT's earnings call transcripts at https://spokenalpha.com/companies/ABT. Each call links to attributed speakers and parsed analyst Q&A.
ABBOTT LABORATORIES (ABT) held its most recent earnings call on 2026-07-16, covering fiscal Q2 2026.
ABBOTT LABORATORIES (ABT) operates in the Healthcare sector (Medical Devices industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-20 | — | $1.43 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-15 | $1.31 | $1.28 | +2.3% | $12.59B | — | — | EODHD |
| Q1 FY2026 | 2026-04-15 | $1.15 | $1.15 | 0.0% | $11.16B | — | — | EODHD |
| Q4 FY2025 | 2026-01-21 | $1.50 | $1.49 | +0.7% | $11.46B | — | — | EODHD |
| Q3 FY2025 | 2025-10-14 | $1.30 | $1.30 | 0.0% | $11.37B | — | — | EODHD |
| Q2 FY2025 | 2025-07-16 | $1.26 | $1.26 | 0.0% | $11.14B | — | — | EODHD |
| Q1 FY2025 | 2025-04-15 | $1.09 | $1.07 | +1.9% | $10.36B | — | — | EODHD |
| Q4 FY2024 | 2025-01-21 | $1.34 | $1.34 | 0.0% | $10.97B | — | — | EODHD |
| Q3 FY2024 | 2024-10-15 | $1.21 | $1.20 | +0.8% | $10.63B | — | — | EODHD |
| Q2 FY2024 | 2024-07-17 | $1.14 | $1.10 | +3.6% | $10.38B | — | — | EODHD |
| Q1 FY2024 | 2024-04-16 | $0.98 | $0.95 | +3.2% | $9.96B | — | — | EODHD |
| Q4 FY2023 | 2024-01-23 | $1.19 | $1.19 | 0.0% | $10.24B | — | — | EODHD |
| Q3 FY2023 | 2023-10-17 | $1.14 | $1.10 | +3.6% | $10.14B | — | — | EODHD |
| Q2 FY2023 | 2023-07-19 | $1.08 | $1.05 | +2.9% | $9.98B | — | — | EODHD |
| Q1 FY2023 | 2023-04-18 | $1.03 | $0.99 | +4.0% | $9.75B | — | — | EODHD |
| Q4 FY2022 | 2023-01-24 | $1.03 | $0.94 | +9.6% | $10.09B | — | — | EODHD |
| Q3 FY2022 | 2022-10-18 | $1.15 | $0.94 | +22.3% | $10.41B | — | — | EODHD |
| Q2 FY2022 | 2022-07-19 | $1.43 | $1.14 | +25.4% | $11.26B | — | — | EODHD |
| Q1 FY2022 | 2022-04-19 | $1.73 | $1.46 | +18.5% | $11.89B | — | — | EODHD |
| Q4 FY2021 | 2022-01-25 | $1.32 | $1.21 | +9.1% | $11.47B | — | — | EODHD |
Source: EODHD. ABT reported actuals as published; sparse fields render as —.